Our PATHWAYS TO THE FUTURE story is about an unconventional approach to developing new psychiatric drugs. Based on an initiative by the National Institute of Mental Health, it’s called “Fast-Fail” and is designed to weed out the weakest drug candidates early in the process, to save time and money. In its first comprehensive test, a team led by two BBRF grantees and including 11 other BBRF grantees, Scientific Council members and prize winners, demonstrated the approach using a potential drug to treat anhedonia—the inability to experience or seek pleasure—which is seen in a number of psychiatric disorders including depression, anxiety, and PTSD.
Read More
A World Expert Discusses What Research and Personal Experience Have Taught Him
Read More
Foundation President and CEO, Jeffrey Borenstein, M.D. is quoted in an article from Scientific American about a research study featured in the Foundation's top 10 research advancements of 2016.
Read More
Allen Zeitlin is a third year med student at Michigan State University in Grand Rapids, with interests in psychiatry and neurology. This has a lot to do with the time he spent in the Middle East, serving in the military.
Read More
Donna Morrissey invests in brain and behavior research hoping for development of better diagnostic tools for people, like her son, living with mental illness.
The misdiagnosis of Donna Morrissey’s son, Michael, mobilized her as an advocate for mental health research.
Read More